Novo Nordisk announced on Thursday that Camilla Sylvest, who was in charge of commercial strategy and corporate affairs, has opted to depart from the company. Following her departure, Ludovic Helfgott, the head of Novo's rare disease unit, will take over the roles related to product and portfolio strategy. This includes overseeing commercial strategy, medical affairs, and business development for all therapy areas. Stine Jacobsen reported this news, edited by Terje Solsvik.